HRP20170679T1 - Epitopi sklerostina - Google Patents
Epitopi sklerostina Download PDFInfo
- Publication number
- HRP20170679T1 HRP20170679T1 HRP20170679TT HRP20170679T HRP20170679T1 HR P20170679 T1 HRP20170679 T1 HR P20170679T1 HR P20170679T T HRP20170679T T HR P20170679TT HR P20170679 T HRP20170679 T HR P20170679T HR P20170679 T1 HRP20170679 T1 HR P20170679T1
- Authority
- HR
- Croatia
- Prior art keywords
- bone
- disease
- bone loss
- polypeptide
- monoclonal antibody
- Prior art date
Links
- 102000019307 Sclerostin Human genes 0.000 title 1
- 108050006698 Sclerostin Proteins 0.000 title 1
- 206010065687 Bone loss Diseases 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 208000001132 Osteoporosis Diseases 0.000 claims 7
- 210000000988 bone and bone Anatomy 0.000 claims 7
- 101000711796 Homo sapiens Sclerostin Proteins 0.000 claims 5
- 208000029725 Metabolic bone disease Diseases 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 102000058171 human SOST Human genes 0.000 claims 5
- 206010049088 Osteopenia Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- 208000027414 Legg-Calve-Perthes disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 238000010494 dissociation reaction Methods 0.000 claims 2
- 230000005593 dissociations Effects 0.000 claims 2
- 201000010103 fibrous dysplasia Diseases 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 230000011164 ossification Effects 0.000 claims 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010000599 Acromegaly Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 201000000736 Amenorrhea Diseases 0.000 claims 1
- 206010001928 Amenorrhoea Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000010392 Bone Fractures Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006956 Calcium deficiency Diseases 0.000 claims 1
- 206010008723 Chondrodystrophy Diseases 0.000 claims 1
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims 1
- 201000000304 Cleidocranial dysplasia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims 1
- 241000699800 Cricetinae Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000000088 Enchondromatosis Diseases 0.000 claims 1
- 208000024720 Fabry Disease Diseases 0.000 claims 1
- 206010017076 Fracture Diseases 0.000 claims 1
- 208000015872 Gaucher disease Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 201000002980 Hyperparathyroidism Diseases 0.000 claims 1
- 206010020707 Hyperparathyroidism primary Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 206010058359 Hypogonadism Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 208000017670 Juvenile Paget disease Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000017924 Klinefelter Syndrome Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000002720 Malnutrition Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000030136 Marchiafava-Bignami Disease Diseases 0.000 claims 1
- 208000001826 Marfan syndrome Diseases 0.000 claims 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 claims 1
- 208000012583 Menkes disease Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 208000009905 Neurofibromatoses Diseases 0.000 claims 1
- 208000035175 Oligomenorrhea Diseases 0.000 claims 1
- 206010030295 Oligomenorrhoea Diseases 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010031264 Osteonecrosis Diseases 0.000 claims 1
- 208000013612 Parathyroid disease Diseases 0.000 claims 1
- 208000010067 Pituitary ACTH Hypersecretion Diseases 0.000 claims 1
- 208000020627 Pituitary-dependent Cushing syndrome Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 201000000981 Primary Hyperparathyroidism Diseases 0.000 claims 1
- 208000002607 Pseudarthrosis Diseases 0.000 claims 1
- 241000700159 Rattus Species 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 208000005770 Secondary Hyperparathyroidism Diseases 0.000 claims 1
- 208000002903 Thalassemia Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims 1
- 208000026928 Turner syndrome Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047623 Vitamin C deficiency Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 208000008321 Winchester syndrome Diseases 0.000 claims 1
- 208000008919 achondroplasia Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 208000022567 adolescent idiopathic scoliosis Diseases 0.000 claims 1
- 201000007930 alcohol dependence Diseases 0.000 claims 1
- 231100000540 amenorrhea Toxicity 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 208000015322 bone marrow disease Diseases 0.000 claims 1
- 230000037118 bone strength Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 229940096384 chicken egg white lysozyme Drugs 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 210000003054 facial bone Anatomy 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 229960002897 heparin Drugs 0.000 claims 1
- 229920000669 heparin Polymers 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 208000011111 hypophosphatemic rickets Diseases 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 208000024884 ischemic bone disease Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 239000004973 liquid crystal related substance Substances 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 230000001071 malnutrition Effects 0.000 claims 1
- 235000000824 malnutrition Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 201000004931 neurofibromatosis Diseases 0.000 claims 1
- 208000015380 nutritional deficiency disease Diseases 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 208000005368 osteomalacia Diseases 0.000 claims 1
- 208000029985 osteonecrosis of the jaw Diseases 0.000 claims 1
- 206010031281 osteopoikilosis Diseases 0.000 claims 1
- 208000028169 periodontal disease Diseases 0.000 claims 1
- 208000001685 postmenopausal osteoporosis Diseases 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 201000006409 renal osteodystrophy Diseases 0.000 claims 1
- 238000004007 reversed phase HPLC Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000002784 sclerotic effect Effects 0.000 claims 1
- 208000010233 scurvy Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 210000003625 skull Anatomy 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Table Devices Or Equipment (AREA)
Claims (12)
1. Postupak za proizvodnju polipeptida koji je imunogeni dio humanog sklerostina, naznačen time, da obuhvaća sljedeće korake:
a) tretiranja humanog sklerostina radi postizanja potpune triptičke digestije;
b) sakupljanja uzorka triptičkog digesta prosječne molekulske mase od 7,122.0 Daltona (teorijska masa 7121.5 Daltona) kako je određeno masenom spektrometrijom elektrosprej ionizacije tekućih kristala ili retencijskim vremenom od oko 20.6 minuta kako je određeno eluiranjem HPLC kolone na reverznim fazama s linearnim gradijentom od 0.05% trifluoroctene kiseline (TFA) do 90% acetonitrila u 0.05% TFA pri brzini protoka od 0.2 ml/min; i
c) pročišćavanja imunogenog dijela.
2. Polipeptid, naznačen time, da se može dobiti postupkom iz patentnog zahtjeva 1.
3. Neterapijski postupak stvaranja protutijela, naznačen time, da se sastoji od primjene polipeptida iz patentnog zahtjeva 2 na životinju koja je štakor, hrčak, zec ili miš.
4. Monoklonsko protutijelo koje se veže za polipeptid iz patentnog zahtjeva 2, naznačen time, da se veže za humani sklerostin s disocijacijskom konstantom manjom ili jednakom od 1 x 10-9 M kako je izmjereno površinskom plazmonskom rezonancijom; te povećava barem jednu formaciju kosti, mineralnu gustoću kosti, mineralni sastav kosti, koštanu masu, kvalitetu kosti i jačinu kosti kod sisavca.
5. Monoklonsko protutijelo prema patentnom zahtjevu 4, naznačeno time, da se veže na polipeptide T20, T20.6, T21-22 i N22.7-23.5 te ima minimalno detektabilno vezanje za polipeptide T19.2, N14.6 and N18.6, pri čemu polipeptid T20 ima odsječke DVSEYSCREL HFTRYVTDGP CRSAKPVTEL VCSGQCGPAR i PSGPDFR CIPDRYRAQR VQLLCPGGEA PRARKVRLVA SCKCKRLT R; pri čemu polipeptid T20.6 ima odsječke DVSEYSCREL HFTR, WWRPSGPPFR CIPDRYR, SAKPVTELVC SGQCGPAR i LVASCKCKRL TR;
pri čemu polipeptid T21-22 ima odsječke DVSEYSCREL HFTRYVTDGP CRSAKPVTEL VCSGQCGPAR i WWRPSGPDFR CIPDRYRAQR VQLLCPGGEA PRARKVRLVA SCKCKRLTR; pri čemu polipeptid N22.7-23.5 ima odsječke DVSEYSCREL HFTRYVTDGP CRSAKPVTEL VCSGQCGPAR LLPNAIGRGK WWRPSGPDFR CIPDRYRAQR VQLLCPGGEA PRARKVRLVA SCKCKRLTRF HNQS;
pri čemu polipeptid T19.2 ima odsječke YVTDGP CR i VQLLCPGGEA PR; pri čemu polipeptid N14.6 ima odsječke ENGGRPPHHPF, EIIPELGFYP EPPP i DFGTEAARPQ KGRKPRPRAR SAKANQA; i pri čemu polipeptid N18.6 ima odsječke DATEIIPELG EYPEPPPELE NNKTMNRAEN GGRPPHHPFE TK.
6. Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 4 ili 5, naznačeno time, da je fragment F(ab')2, Fab, Fab' ili Fv.
7. Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 4 do 6, naznačeno time, daje humanizirano protutijelo ili humano protutijelo.
8. Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 4 do 7, naznačeno time, da se veže za humani sklerostin s disocijacijskom konstantom manjom od ili jednakom 1 x 10-10 M, manjom od ili jednakom 1 x 10~11 M ili koja je manja od ili jednaka 1 x 10-12 M.
9. Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 4 do 8, naznačeno time, da se veže za humani sklerostin s afinitetom, kako je izmjereno površinskom plazmonskom rezonancijom, koja je najmanje 50, 100, 250, 500, 1000 ili 10,000 puta veća od afiniteta za lizozim kokošjeg bjelanjka.
10. Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 4 do 9, naznačeno time, da je za uporabu u liječenju osteoporoze ili osteopenije.
11. Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 4 do 9, naznačen time, da se koristi u postupku liječenja osteopenije, osteoporoze ili gubitka kosti usljed ahondroplazije, kleidokranijalne disostoze, enhondromatoze, fibrozne displazije, Gaucherove bolesti, hipofosfatemičnog rahitisa, Marfanovog sindroma, višestruke nasljedne egzotoze, neurofibromatoze, nesavršene osteogeneze, osteopoikilozisa, sklerotične lezije, pseudoartroze, piogenog osteomijelitisa, bolesti periodonta, gubitka kosti kao posljedica uzimanja protu-epileptičkog lijeka, primarne i sekundarne hiperparatiroidoze, obiteljskih sindroma hiperparatiroidoze, gubitka kosti usljed bestežinskog stanja, osteoporoze u muškaraca, gubitka kosti nakon menopauze, osteoartritisa, bubrežne osteodistrofije, infiltracijskog poremećaja kosti, gubitak oralne kosti, osteonekroze čeljusti, juvenilne Pagetove bolesti, meloreostoze, metaboličke bolesti kostiju, mastocitoze, srpaste anemije/bolesti, gubitka kosti povezane s usadkom, gubitak kosti povezane s usadkom bubrega, sistemskog lupusa eritematozusa, ankiloznog spondilitisa, epilepsije, juvenilnog artritisa, talasemije, mukopolisaharidoze, Fabrijeve bolesti, Turnerovog sindroma, Dovvnovog sindroma, Klinefelterovog sindroma, lepre, Perthesove bolesti, adolescentske idiopatske skolioze, početne infantilne više-sustavne upalne bolesti, Winchesterovog sindroma, Menkesove bolesti, Wilsonove bolesti, ishemične koštane bolesti (poput Legg-Calve-Perthesove bolesti, regionalne migratome osteoporoze), anemičnih stanja, stanja uzrokovanih steroidima, gubitka kosti izazvane glukokortikoidima, gubitka kosti izazvane heparinom, poremećaja koštane srži, skorbuta, pothranjenosti, nedostatka kalcija, idiopatske osteopenije ili osteoporze, kongenitalne osteopenije ili osteoporoze, alkoholizma, kroničnog oboljenja jetara, stanja poslije menopauze, kroničnih upalnih stanja, reumatoidinog artritisa, upalne bolesti crijeva, ulceroznog kolitisa, upalnog kolitisa, Crohnove bolesti, oligomenoreje, amenoreje, trudnoće, dijabetes melitusa, hipertiroidizma, poremećaja štitnjače, paratiroidnih poremećaja, Cushingove bolesti, akromegalije, hipogonadizma, imobilizacije ili neuporabe, sindroma refleksne simpatetičke distrofije, regionalne osteoporoze, osteomalacije, gubitka kosti usljed zamjene zgloba, gubitka kosti povezane s HIV-om, gubitka kosti povezane s hormonom rasta, gubitka kosti povezane s cističnom fibrozom, fibroznom displazijom, gubitka kosti povezane s kemoterapijom, gubitka kosti izazvane tumorom, gubitkom kosti povezane s karcinomom, gubitka kosti zbog ablativne hormonske terapije, višestrukog mijeloma, gubitka kosti izazvane uzimanjem lijekova, anoreksija nervoza, gubitka kostiju lica usljed bolesti, gubitka kranijalne kosti usljed bolesti, gubitka čeljusne kosti usljed bolesti, gubitka kosti lubanje usljed bolesti ili gubitka kosti usljed putovanja u svemir.
12. Monoklonsko protutijelo prema bilo koje od patentnih zahtjeva 4 -9, naznačeno time, da je za uporabu u poboljšavanju ishoda kod ortopedskih procedura, zubnih procedura, operacija usadka, zamjene zglobova, presađivanja kosti, kozmetičke operacije kosti ili reparacije poput liječenja loma, zacjeljivanja bez srastanja, zakašnjelog zacjeljivanja ili rekonstrukcije lica.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67758305P | 2005-05-03 | 2005-05-03 | |
| US77684706P | 2006-02-24 | 2006-02-24 | |
| US78224406P | 2006-03-13 | 2006-03-13 | |
| US79264506P | 2006-04-17 | 2006-04-17 | |
| US11/410,540 US8003108B2 (en) | 2005-05-03 | 2006-04-25 | Sclerostin epitopes |
| EP10014373.4A EP2301961B9 (en) | 2005-05-03 | 2006-04-28 | Sclerostin epitopes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20170679T1 true HRP20170679T1 (hr) | 2017-07-14 |
| HRP20170679T4 HRP20170679T4 (hr) | 2023-10-13 |
Family
ID=36956127
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170514TT HRP20170514T4 (hr) | 2005-05-03 | 2006-04-28 | Epitopi sklerostina |
| HRP20170679TT HRP20170679T4 (hr) | 2005-05-03 | 2006-04-28 | Epitopi sklerostina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170514TT HRP20170514T4 (hr) | 2005-05-03 | 2006-04-28 | Epitopi sklerostina |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US8003108B2 (hr) |
| EP (6) | EP2301961B9 (hr) |
| JP (7) | JP5680823B2 (hr) |
| CA (1) | CA2607276C (hr) |
| CY (2) | CY1118977T1 (hr) |
| DK (2) | DK2301961T4 (hr) |
| ES (5) | ES2624643T5 (hr) |
| FI (2) | FI2301961T4 (hr) |
| HR (2) | HRP20170514T4 (hr) |
| HU (2) | HUE033718T2 (hr) |
| LT (2) | LT2301961T (hr) |
| MX (1) | MX348432B (hr) |
| MY (1) | MY174493A (hr) |
| PL (2) | PL2251351T5 (hr) |
| PT (2) | PT2251351T (hr) |
| SI (2) | SI2301961T2 (hr) |
| WO (1) | WO2006119062A2 (hr) |
Families Citing this family (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2261335B1 (en) | 1998-11-27 | 2017-06-14 | UCB Pharma S.A. | Compositions and methods for increasing bone mineralisation |
| WO2003106657A2 (en) | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| US7585501B2 (en) | 2002-06-14 | 2009-09-08 | Stowers Institute For Medical Research | Compositions and methods for treating kidney disease |
| US7893218B2 (en) * | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| AU2004262640B2 (en) | 2003-06-16 | 2010-12-23 | Ucb Manufacturing, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| US9862770B2 (en) | 2005-10-19 | 2018-01-09 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| US20100226884A1 (en) | 2009-01-20 | 2010-09-09 | Immunomedics, Inc. | Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R) |
| US8883162B2 (en) | 2005-10-19 | 2014-11-11 | Ibc Pharmaceuticals, Inc. | Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors |
| EP4342995A3 (en) | 2006-03-31 | 2024-05-15 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| UA100116C2 (ru) | 2006-06-08 | 2012-11-26 | Чугей Сейяку Кабусики Кайся | Профилактика или лечение воспалительного заболевания |
| EP2097450A2 (en) * | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2094731A2 (en) * | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
| FI3345607T3 (fi) | 2006-12-29 | 2022-11-30 | Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia | |
| WO2008101234A2 (en) * | 2007-02-16 | 2008-08-21 | Sloan-Kettering Institute For Cancer Research | Anti ganglioside gd3 antibodies and uses thereof |
| MY149129A (en) * | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| CL2008002775A1 (es) * | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| US9096651B2 (en) | 2007-09-26 | 2015-08-04 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substitution in CDR |
| RU2526512C2 (ru) | 2007-09-26 | 2014-08-20 | Чугаи Сейяку Кабусики Кайся | Модифицированная константная область антитела |
| TWI489993B (zh) * | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| MX2010004761A (es) | 2007-11-02 | 2010-05-19 | Novartis Ag | Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6). |
| AU2008332276B2 (en) | 2007-12-05 | 2014-02-27 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agent for pruritus |
| EP2236604B1 (en) | 2007-12-05 | 2016-07-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-nr10 antibody and use thereof |
| EA201070740A1 (ru) | 2007-12-14 | 2010-12-30 | Эмджен Инк. | Способ лечения перелома кости антителами против склеростина |
| PL3514180T3 (pl) | 2008-04-11 | 2024-08-12 | Chugai Seiyaku Kabushiki Kaisha | Cząsteczka wiążąca antygen zdolna do wiązania dwóch lub więcej cząsteczek antygenu w sposób powtarzalny |
| WO2010027797A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics Inc. | T-cell receptor antibodies and methods of use thereof |
| US20100082438A1 (en) * | 2008-10-01 | 2010-04-01 | Ronnie Jack Garmon | Methods and systems for customer performance scoring |
| JP5139517B2 (ja) * | 2008-12-05 | 2013-02-06 | 中外製薬株式会社 | 抗ｎｒ１０抗体、およびその利用 |
| KR20160062207A (ko) * | 2008-12-05 | 2016-06-01 | 추가이 세이야쿠 가부시키가이샤 | 항ｎｒ１０ 항체 및 그의 이용 |
| JP2010210772A (ja) * | 2009-03-13 | 2010-09-24 | Dainippon Screen Mfg Co Ltd | 液晶表示装置の製造方法 |
| JP5787446B2 (ja) | 2009-03-19 | 2015-09-30 | 中外製薬株式会社 | 抗体定常領域改変体 |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| EP3248619A3 (en) * | 2009-06-04 | 2018-03-07 | Novartis AG | Methods for identification of sites for igg conjugation |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| EA025367B1 (ru) * | 2009-08-17 | 2016-12-30 | Тракон Фармасьютикалз, Инк. | Комбинированная терапия рака с помощью антител против эндоглина и агентов против vegf |
| CA2787074A1 (en) * | 2010-01-19 | 2011-07-28 | Immunomedics, Inc. | Novel antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| MX362591B (es) | 2010-11-05 | 2019-01-25 | Novartis Ag | Uso de antagonistas de il-17. |
| TWI812066B (zh) | 2010-11-30 | 2023-08-11 | 日商中外製藥股份有限公司 | 具有鈣依存性的抗原結合能力之抗體 |
| AU2012223358A1 (en) * | 2011-03-01 | 2013-09-05 | Amgen Inc. | Sclerostin and DKK-1 bispecific binding agents |
| US9145457B2 (en) * | 2011-03-25 | 2015-09-29 | Amgen Inc. | Sclerostin antibody crystals and formulations thereof |
| PL3404041T3 (pl) | 2011-04-19 | 2020-12-14 | Amgen Inc. | Sposób leczenia osteoporozy |
| US20140056912A1 (en) | 2011-04-29 | 2014-02-27 | Novartis Ag | Methods of treating squamous cell carcinoma |
| AU2012290083B2 (en) | 2011-08-04 | 2017-07-20 | Amgen Inc. | Method for treating bone gap defects |
| AU2012362898B2 (en) | 2011-12-28 | 2017-11-09 | Amgen, Inc. | Method of treating alveolar bone loss through the use of anti-sclerostin antibodies |
| US20130302322A1 (en) | 2012-05-11 | 2013-11-14 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| EP2869844B2 (en) | 2012-07-05 | 2023-06-21 | UCB Pharma S.A. | Treatment for bone diseases |
| US10431325B2 (en) | 2012-08-03 | 2019-10-01 | Novartis Ag | Methods to identify amino acid residues involved in macromolecular binding and uses therefor |
| US20140079699A1 (en) | 2012-08-31 | 2014-03-20 | Five Prime Therapeutics, Inc. | Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r) |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| UY35148A (es) | 2012-11-21 | 2014-05-30 | Amgen Inc | Immunoglobulinas heterodiméricas |
| WO2014118705A1 (en) | 2013-01-31 | 2014-08-07 | Novartis Ag | Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists |
| PE20151901A1 (es) | 2013-02-22 | 2016-01-13 | Abbvie Stemcentrx Llc | Nuevos conjugados de anticuerpos y usos de los mismos |
| TWI636063B (zh) | 2013-03-08 | 2018-09-21 | 美國禮來大藥廠 | 結合ｉｌ－２３之抗體 |
| WO2014144817A2 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Inhibitory polypeptides specific to wnt inhibitors |
| WO2014155278A2 (en) | 2013-03-26 | 2014-10-02 | Novartis Ag | Methods of treating autoimmune diseases using il-17 antagonists |
| AU2014312215B2 (en) | 2013-08-28 | 2020-02-27 | Abbvie Stemcentrx Llc | Site-specific antibody conjugation methods and compositions |
| CN106550593A (zh) | 2014-02-21 | 2017-03-29 | 艾伯维施特姆森特克斯有限责任公司 | 用于黑素瘤的抗‑dll3抗体和药物缀合物 |
| EA037561B1 (ru) | 2014-06-23 | 2021-04-14 | Файв Прайм Терапьютикс, Инк. | Способы лечения заболеваний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| WO2016065181A1 (en) | 2014-10-23 | 2016-04-28 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| JP6920989B2 (ja) | 2014-10-29 | 2021-08-18 | ファイヴ プライム セラピューティクス インク | がんのための併用療法 |
| JP2017537084A (ja) | 2014-11-12 | 2017-12-14 | トラコン ファーマシューティカルズ、インコーポレイテッド | 抗エンドグリン抗体及びその用途 |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| MA41142A (fr) | 2014-12-12 | 2017-10-17 | Amgen Inc | Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| TW201630937A (zh) | 2014-12-22 | 2016-09-01 | 戊瑞治療有限公司 | 用於治療ｐｖｎｓ之抗－ｃｓｆ１ｒ抗體 |
| SI3269735T1 (sl) | 2015-03-13 | 2020-12-31 | Jiangsu Hengrui Medicine Co. Ltd. | Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega |
| PT3283527T (pt) | 2015-04-13 | 2021-03-03 | Five Prime Therapeutics Inc | Terapêutica de combinação para o cancro |
| CN107614016B (zh) | 2015-04-14 | 2022-06-17 | 中外制药株式会社 | 包含il-31拮抗剂作为活性成分的用于预防和/或治疗特应性皮炎的药物组合物 |
| TWI715587B (zh) * | 2015-05-28 | 2021-01-11 | 美商安可美德藥物股份有限公司 | Ｔｉｇｉｔ結合劑和彼之用途 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| CL2016000164A1 (es) * | 2016-01-21 | 2016-07-29 | Pontificia Universidad Católica De Chile | Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv. |
| GB201604124D0 (en) | 2016-03-10 | 2016-04-27 | Ucb Biopharma Sprl | Pharmaceutical formulation |
| EA039540B1 (ru) * | 2016-03-25 | 2022-02-08 | Онкомед Фармасьютикалс, Инк. | Связывающие tigit агенты и варианты их применения |
| LT3484916T (lt) | 2016-07-12 | 2021-04-26 | H. Lundbeck A/S | Antikūnai, būdingi hiperfosforilintam tau, ir jų naudojimo būdai |
| KR20190037261A (ko) | 2016-08-08 | 2019-04-05 | 암젠 인크 | 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법 |
| CA3044664C (en) | 2016-11-30 | 2022-11-22 | Oncomed Pharmaceuticals, Inc. | Methods for treatment of cancer comprising tigit-binding agents |
| WO2018115879A1 (en) | 2016-12-21 | 2018-06-28 | Mereo Biopharma 3 Limited | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
| KR20190096409A (ko) | 2016-12-21 | 2019-08-19 | 메레오 바이오파마 3 리미티드 | 불완전 골형성증 치료에서의 항-스클레로스틴 항체의 용도 |
| JP7191833B2 (ja) | 2017-01-30 | 2022-12-19 | 中外製薬株式会社 | 抗スクレロスチン抗体およびその使用 |
| MA48464A (fr) | 2017-04-28 | 2020-03-04 | Amgen Inc | Dipeptides n-acétylés et non acétylés contenant de l'arginine destinés à réduire la viscosité de compositions visqueuses de polypeptides thérapeutiques |
| JP7237022B2 (ja) | 2017-08-01 | 2023-03-10 | アムジエン・インコーポレーテツド | 質量分析法による分析用ポリペプチド試料のリアルタイム調製のためのシステム及び方法 |
| KR102577670B1 (ko) | 2017-08-01 | 2023-09-12 | 암젠 인크 | 샘플의 실시간 글리칸 분석을 수행하기 위한 시스템 및 방법 |
| US11421034B2 (en) | 2017-09-13 | 2022-08-23 | Five Prime Therapeutics, Inc. | Combination anti-CSF1R and anti-PD-1 antibody combination therapy for pancreatic cancer |
| US20210041453A1 (en) | 2018-03-13 | 2021-02-11 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| MA52015A (fr) | 2018-03-13 | 2021-01-20 | Amgen Inc | Digestion séquentielle de polypeptides pour une analyse par spectrométrie de masse |
| WO2019191534A1 (en) | 2018-03-30 | 2019-10-03 | Amgen Inc. | C-terminal antibody variants |
| GB201810746D0 (en) | 2018-06-29 | 2018-08-15 | Mereo Biopharma 3 Ltd | Use of sclerostin antagonist |
| US20210308265A1 (en) | 2018-08-10 | 2021-10-07 | Amgen Inc. | Method of preparing an antibody pharmaceutical formulation |
| CA3126018A1 (en) | 2018-12-14 | 2020-06-18 | Amgen Inc. | System suitability method for use with protein concentration determination by slope |
| WO2020168156A1 (en) | 2019-02-14 | 2020-08-20 | Amgen Inc. | Systems and methods for preparing a sample and performing a real-time assay of the sample |
| CA3127817A1 (en) | 2019-02-20 | 2020-08-27 | Amgen Inc. | Methods of determining protein stability |
| EP3935396A1 (en) | 2019-03-04 | 2022-01-12 | Amgen Inc. | In vivo reversibility of high molecular weight species |
| CA3133459A1 (en) | 2019-03-27 | 2020-10-01 | Amgen Inc. | Methods of fingerprinting therapeutic proteins via a two-dimensional (2d) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products |
| CA3138941A1 (en) | 2019-06-05 | 2020-12-10 | Amgen Inc. | Methods of identifying attributes of therapeutic proteins |
| AU2020331282A1 (en) | 2019-08-12 | 2022-03-31 | Amgen Inc. | Anti-sclerostin antibody formulations |
| WO2021030423A1 (en) * | 2019-08-13 | 2021-02-18 | The Feinstein Institutes For Medical Research | Tetranectin-targeting monoclonal antibodies to fight against lethal sepsis and other pathologies |
| EP4062933A4 (en) | 2019-11-20 | 2023-12-13 | Chugai Seiyaku Kabushiki Kaisha | ANTIBODY CONTAINING PREPARATION |
| JP2023543167A (ja) | 2020-09-18 | 2023-10-13 | アムジエン・インコーポレーテツド | ペプチドマッピング分析のための試料を処理する方法 |
| AU2021376246A1 (en) | 2020-11-05 | 2023-06-08 | Amgen Inc. | Materials and methods for protein processing |
| CA3237662A1 (en) | 2021-11-09 | 2023-05-19 | Amgen Inc. | Production of therapeutic proteins |
| WO2024259275A1 (en) | 2023-06-14 | 2024-12-19 | Bristol-Myers Squibb Company | Near real time sialic acid quantitation of glycoproteins |
| WO2025019728A1 (en) | 2023-07-19 | 2025-01-23 | Amgen Inc. | Methods of buffer preparation for a therapeutic protein formulation |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US32011A (en) | 1861-04-09 | Coffee-pot | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4411993A (en) | 1981-04-29 | 1983-10-25 | Steven Gillis | Hybridoma antibody which inhibits interleukin 2 activity |
| US4427115A (en) | 1981-10-19 | 1984-01-24 | Laipply Thomas C | One piece alcohol preparation device |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| USRE32011E (en) | 1981-12-14 | 1985-10-22 | Scripps Clinic And Research Foundation | Ultrapurification of factor VIII using monoclonal antibodies |
| JPS58117537A (ja) | 1982-01-06 | 1983-07-13 | Toray Ind Inc | 感光性樹脂組成物 |
| US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| DE3417525C1 (de) | 1984-05-11 | 1986-01-09 | Matter + Siegmann Ag, Wohlen | Vorrichtung zur quantitativen und qualitativen Erfassung von kohlenwasserstoffhaltigen Schwebeteilchen in Gasen |
| US4902614A (en) | 1984-12-03 | 1990-02-20 | Teijin Limited | Monoclonal antibody to human protein C |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5177197A (en) | 1990-02-27 | 1993-01-05 | Ludwig Institute For Cancer Research | Isolated nucleotide sequence expressing human transforming growth factor-β1-binding protein |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| US5837456A (en) * | 1990-06-11 | 1998-11-17 | Nexstar Pharmaceuticals, Inc. | High affinity oligonucleotide ligands to chorionic gonadotropin hormone and related glycoprotein hormones |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| JPH04141095A (ja) | 1990-10-02 | 1992-05-14 | Chemo Sero Therapeut Res Inst | 組換え抗ｈｉｖ改変抗体および改変抗体の調製方法 |
| US5070108A (en) | 1990-10-12 | 1991-12-03 | Trustees Of The University Of Pennsylvania | Methods of treating osteoporosis, increasing bone mineral content and preventing the occurrence of compression fractures in a mammal |
| WO1992006693A1 (en) | 1990-10-22 | 1992-04-30 | Fox Chase Cancer Center | Dna construct for providing rna therapy |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| DK0628639T3 (da) | 1991-04-25 | 2000-01-24 | Chugai Pharmaceutical Co Ltd | Rekonstitueret humant antistof mod human interleukin-6-receptor |
| CA2164505A1 (en) | 1993-06-07 | 1994-12-22 | Phillip W. Berman | Hiv envelope polypeptides |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5453492A (en) | 1993-07-28 | 1995-09-26 | La Jolla Cancer Research Foundation | 60 kDa transforming growth factor-β-binding protein and its use to detect or purify TGF-β |
| US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5863738A (en) | 1994-04-29 | 1999-01-26 | Creative Biomolecules, Inc. | Methods of antagonizing OP-1 binding to a cell surface receptor utilizing ALK polypeptides |
| US5846770A (en) | 1994-11-22 | 1998-12-08 | Genetics Institute, Inc. | DNA molecules encoding human chordin |
| US6057421A (en) | 1994-11-30 | 2000-05-02 | Immpheron, Inc. | Variable heavy and light chain regions of murine monoclonal antibody 1F7 |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| CA2220912A1 (en) | 1995-06-05 | 1996-12-12 | Gregg A. Hastings | Human ccn-like growth factor |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| DK0912738T3 (da) | 1996-05-22 | 2008-11-17 | Viventia Biotech Inc | Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| US5989909A (en) | 1997-09-26 | 1999-11-23 | Millennium Biotherapeutics, Inc. | Huchordin and uses thereof |
| US6117911A (en) | 1997-04-11 | 2000-09-12 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| ATE386802T1 (de) | 1997-06-12 | 2008-03-15 | Novartis Int Pharm Ltd | Künstliche antikörperpolypeptide |
| US6075007A (en) | 1997-07-17 | 2000-06-13 | Regeneron Pharmaceuticals, Inc. | Modified noggin polypeptide and compositions |
| EP1000152A2 (en) | 1997-08-01 | 2000-05-17 | Genset | 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN MUSCLE AND OTHER MESODERMAL TISSUES |
| US6815201B2 (en) | 1997-09-08 | 2004-11-09 | The Public Health Research Institute Of The City Of New York, Inc. | HIV-1 gp120 V1/V2 domain epitopes capable of generating neutralizing antibodies |
| US6544485B1 (en) | 2001-01-29 | 2003-04-08 | Sharper Image Corporation | Electro-kinetic device with enhanced anti-microorganism capability |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| EP2261335B1 (en) | 1998-11-27 | 2017-06-14 | UCB Pharma S.A. | Compositions and methods for increasing bone mineralisation |
| ATE440109T1 (de) | 1999-06-09 | 2009-09-15 | Genentech Inc | Methoden zur diagnose von tumoren |
| AU4196801A (en) | 2000-03-02 | 2001-09-12 | Amgen Inc | Chordin-like-2 molecules and uses thereof |
| JP2003534813A (ja) | 2000-06-01 | 2003-11-25 | アムジェン インコーポレーテッド | シスチンノットポリペプチド：ｃｌｏａｋｅｄ−２分子およびその使用 |
| WO2001098491A2 (en) | 2000-06-19 | 2001-12-27 | F. Hoffmann-La Roche Ag | Osteolevin gene polymorphisms |
| CA2421056A1 (en) | 2000-09-01 | 2002-03-28 | Genentech, Inc. | A polypeptide for use as a diagnostic marker for the presence of colon tumours |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| CA2374027A1 (en) | 2001-03-13 | 2002-09-13 | The Minister Of National Defence | Cloning, expression, sequencing, and functional enhancement of monoclonal scfv antibody against venezuelan equine encephalitis virus(vee) |
| CA2469025A1 (en) | 2001-12-06 | 2003-06-19 | Biocontrol Systems, Inc. | Sample collection and testing system |
| US20030186915A1 (en) | 2002-02-11 | 2003-10-02 | Yang Pan | Regulatory polynucleotides and uses thereof |
| WO2003073991A2 (en) | 2002-03-01 | 2003-09-12 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
| US7799523B2 (en) | 2002-04-03 | 2010-09-21 | Celltech R & D, Inc. | Association of polymorphisms in the SOST gene region with bone mineral density |
| FR2838379B1 (fr) | 2002-04-12 | 2005-06-24 | Valeo Climatisation | Dispositif de purification de l'air de l'habitacle d'un vehicule automobile |
| US7893218B2 (en) | 2003-06-16 | 2011-02-22 | Stowers Institute For Medical Research | Antibodies that specifically bind SOST peptides |
| WO2003106657A2 (en) | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| CA2504493C (en) | 2002-11-01 | 2015-12-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preventing infections from bioterrorism agents with immunostimulatory cpg oligonucleotides |
| DE10255152A1 (de) | 2002-11-26 | 2004-06-03 | Von Langen Ursula Lang | Schadstoffsauger |
| FI115753B (fi) | 2002-11-29 | 2005-07-15 | Paloheimo Raija | Menetelmä ja sovitelma kahvijuomien valmistamiseksi |
| US7642238B2 (en) | 2002-12-05 | 2010-01-05 | Shaughnessy John D | Molecular determinants of myeloma bone disease and uses thereof |
| US20040141875A1 (en) | 2003-01-15 | 2004-07-22 | Rajiv Doshi | System and method for treating microorganisms within motor vehicle heating, ventilation, and air conditioning units |
| EP1608399B1 (en) | 2003-03-14 | 2012-01-11 | Ucb Manufacturing, Inc. | Complex of sclerostin and noggin or chordin, and agents that modulate the formation of said complex |
| CU23403A1 (es) | 2003-04-23 | 2009-08-04 | Centro Inmunologia Molecular | Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores |
| AU2004262640B2 (en) | 2003-06-16 | 2010-12-23 | Ucb Manufacturing, Inc. | Antibodies specific for sclerostin and methods for increasing bone mineralization |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US8003108B2 (en) | 2005-05-03 | 2011-08-23 | Amgen Inc. | Sclerostin epitopes |
| US7592429B2 (en) | 2005-05-03 | 2009-09-22 | Ucb Sa | Sclerostin-binding antibody |
| EP2097450A2 (en) | 2006-11-10 | 2009-09-09 | Amgen Inc. | Antibody-based diagnostics and therapeutics |
| EP2094731A2 (en) | 2006-11-10 | 2009-09-02 | UCB Pharma S.A. | Anti human sclerostin antibodies |
| WO2008092894A1 (en) | 2007-02-02 | 2008-08-07 | Novartis Ag | Modulators of sclerostin binding partners for treating bone-related disorders |
| MY149129A (en) | 2007-03-20 | 2013-07-15 | Lilly Co Eli | Anti-sclerostin antibodies |
| CL2008002775A1 (es) | 2007-09-17 | 2008-11-07 | Amgen Inc | Uso de un agente de unión a esclerostina para inhibir la resorción ósea. |
| TWI489993B (zh) | 2007-10-12 | 2015-07-01 | Novartis Ag | 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法 |
| MX2010004761A (es) | 2007-11-02 | 2010-05-19 | Novartis Ag | Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6). |
| EA201070740A1 (ru) | 2007-12-14 | 2010-12-30 | Эмджен Инк. | Способ лечения перелома кости антителами против склеростина |
-
2006
- 2006-04-25 US US11/410,540 patent/US8003108B2/en active Active
- 2006-04-28 EP EP10014373.4A patent/EP2301961B9/en active Active
- 2006-04-28 DK DK10014373.4T patent/DK2301961T4/da active
- 2006-04-28 PL PL10006930.1T patent/PL2251351T5/pl unknown
- 2006-04-28 JP JP2008510081A patent/JP5680823B2/ja active Active
- 2006-04-28 HU HUE10006930A patent/HUE033718T2/en unknown
- 2006-04-28 EP EP10006930.1A patent/EP2251351B2/en active Active
- 2006-04-28 DK DK10006930.1T patent/DK2251351T4/da active
- 2006-04-28 ES ES10014373T patent/ES2624643T5/es active Active
- 2006-04-28 ES ES10014372T patent/ES2620684T5/es active Active
- 2006-04-28 MX MX2011003958A patent/MX348432B/es unknown
- 2006-04-28 EP EP10014372.6A patent/EP2295448B2/en active Active
- 2006-04-28 ES ES10014360T patent/ES2901698T3/es active Active
- 2006-04-28 WO PCT/US2006/016345 patent/WO2006119062A2/en active Application Filing
- 2006-04-28 ES ES10006930T patent/ES2619709T5/es active Active
- 2006-04-28 LT LTEP10014373.4T patent/LT2301961T/lt unknown
- 2006-04-28 PT PT100069301T patent/PT2251351T/pt unknown
- 2006-04-28 HR HRP20170514TT patent/HRP20170514T4/hr unknown
- 2006-04-28 MY MYPI20093533A patent/MY174493A/en unknown
- 2006-04-28 FI FIEP10014373.4T patent/FI2301961T4/fi active
- 2006-04-28 LT LTEP10006930.1T patent/LT2251351T/lt unknown
- 2006-04-28 PT PT100143734T patent/PT2301961T/pt unknown
- 2006-04-28 FI FIEP10006930.1T patent/FI2251351T4/fi active
- 2006-04-28 PL PL10014373.4T patent/PL2301961T5/pl unknown
- 2006-04-28 HR HRP20170679TT patent/HRP20170679T4/hr unknown
- 2006-04-28 SI SI200632170T patent/SI2301961T2/sl unknown
- 2006-04-28 HU HUE10014373A patent/HUE032092T2/en unknown
- 2006-04-28 SI SI200632158T patent/SI2251351T2/sl unknown
- 2006-04-28 EP EP10014360.1A patent/EP2345668B1/en active Active
- 2006-04-28 EP EP10014361.9A patent/EP2298800B9/en active Active
- 2006-04-28 EP EP06751835A patent/EP1891100A2/en not_active Withdrawn
- 2006-04-28 ES ES10014361T patent/ES2616985T5/es active Active
- 2006-04-28 CA CA2607276A patent/CA2607276C/en active Active
-
2011
- 2011-04-28 US US13/096,263 patent/US8715663B2/en active Active
-
2014
- 2014-02-20 US US14/185,590 patent/US9353174B2/en active Active
- 2014-05-07 JP JP2014095921A patent/JP2014177470A/ja active Pending
-
2015
- 2015-09-30 JP JP2015192869A patent/JP6158268B2/ja active Active
-
2017
- 2017-02-23 JP JP2017031654A patent/JP2017128583A/ja active Pending
- 2017-03-31 CY CY20171100393T patent/CY1118977T1/el unknown
- 2017-05-09 CY CY20171100495T patent/CY1119127T1/el unknown
-
2018
- 2018-08-06 JP JP2018147689A patent/JP6858733B2/ja active Active
-
2020
- 2020-05-07 JP JP2020081948A patent/JP7010994B2/ja active Active
-
2021
- 2021-12-01 JP JP2021195517A patent/JP7361086B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170679T1 (hr) | Epitopi sklerostina | |
| HRP20160872T1 (hr) | Postupak za inhibiciju resorpcije kosti | |
| HRP20130803T1 (hr) | Sredstva za vezanje sklerostina | |
| US20240209075A1 (en) | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization | |
| HRP20131014T1 (hr) | Kompozicija i postupci poveä†anja mineralizacije kostiju | |
| JP2010539190A5 (hr) | ||
| CN104619342A (zh) | 骨疾病的治疗 | |
| SG182001A1 (en) | Antibodies specific for sclerostin and methods for increasing bone mineralization | |
| MXPA05013796A (en) | Compositions and methods for increasing bone mineralization | |
| AU2012200748A1 (en) | Compositions and methods for increasing bone mineralization |